Navigating Take Home Naloxone: An Antidote for Opioid Toxicity

Navigating Take Home Naloxone: An Antidote for Opioid Toxicity

Dr. Ferghal Armstrong discusses the importance and impact of take-home naloxone with experts Jeremy Szmerling and Dr. Suzanne Neilsen. They explain what take-home naloxone is and its role as an opioid antagonist in combating opioid toxicity, including both heroin and prescription opioid overdoses. They debunk common misconceptions and address barriers to its usage. The episode provides valuable insights for clinicians and highlights the need for wider availability and education around take-home naloxone.

Learning Outcomes:

1. Understand the purpose and availability of take-home naloxone: Take-home naloxone is an opioid antagonist that can be self-administered by a patient using formulations available at pharmacies. It is classified as a pharmacist-only medication and can be dispensed without a prescription.

2. Recognize the importance of take-home naloxone in combating opioid toxicity: Opioid toxicity can lead to serious side effects, including sedation, constipation, nausea, and even respiratory failure and death. Take-home naloxone acts as an antidote to reverse opioid overdoses, making it crucial in saving lives.

3. Dispelling myths and addressing stigma: Despite prevalent misconceptions, studies have shown that providing naloxone does not promote riskier behaviour or increase opioid use. It actually reduces the risks associated with opioid use. It is important for healthcare providers to offer naloxone without stigma to anyone at risk of an opioid overdose.

Actionable Takeaways:

1. Healthcare providers should be aware of the availability of take-home naloxone and its importance in preventing opioid overdoses. They should be prepared to offer and educate patients at risk, regardless of whether they use illicit or prescribed opioids.

2. Language and approach matter: When discussing naloxone with patients, it is crucial to use appropriate language and consider the individual's background and context. Starting with terms like "overdose" or "opioid toxicity" can vary based on the patient's familiarity and comfort level.

3. Overcoming barriers: Clinicians should feel confident in identifying individuals who would benefit from naloxone training and delivery. Offering naloxone to a broad population, rather than selectively targeting high-risk individuals, can lead to more lives being saved.

Quote: "Giving naloxone reduces the risks that people take... providing naloxone, providing education about what an overdose is and how to reverse it, is only going to help someone reduce their risk." - Dr. Suzanne Neilsen

Avsnitt(218)

LAIB - Sublocade

LAIB - Sublocade

Cracking Addiction discusses Sublocade one of the LAIB preparations available and how to commence, maintain and manage any dose changes or complications associated with Sublocade.Sublocade is a long acting injectable buprenorphine (LAIB) manufactured by Invidior that uses the “Atrigel” system to provide for a sustained and prolonged delivery of buprenorphine into the systemic circulation after subcutaneous injection.Discussions and comments in our videos are for informational purposes only and should not replace the advice of your medical professional. Please consult with your doctor before making any changes to your medical treatment or lifestyle.Latest Blogshttps://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses available https://www.meducate.com.au

9 Feb 202215min

LAIB - Buvidal

LAIB - Buvidal

Cracking Addiction discusses Buvidal one of the LAIB preparations available and how to commence, maintain and manage any dose changes or complications associated with Buvidal.Buvidal is a long acting injectable buprenorphine (LAIB) preparation manufactured by Camurus and uses “FluidCrystal” technology to provide for a sustained and prolonged delivery of buprenorphine into the systemic circulation after subcutaneous injection.

3 Feb 202217min

LAIB  Special Circumstances

LAIB Special Circumstances

Cracking Addiction discusses some of the special or difficult circumstances of prescribing LAIBs including intoxicated patients, pregnant patients, patients with chronic disease, patients with acute pain and our management strategies in these situations.

26 Jan 202219min

LAIB first dose considerations

LAIB first dose considerations

Episode 23 of Cracking Addiction explores commencement of patients on LAIB, side effects and risks of LAIB, discussion about precipitated withdrawal and when and how to review patients

20 Jan 202220min

Long Acting Injectable Buprenorphine (LAIB) - Introduction

Long Acting Injectable Buprenorphine (LAIB) - Introduction

An Introduction to Long Acting Injectable Buprenorphine (LAIB)Long acting injectable buprenorphine (LAIB) are long acting buprenorphine depot preparations that are injected subcutaneously and provide patients with a sustained release of buprenorphine for the duration of the depot preparation. Currently, two LAIB products are available for the Australian market. They differ in their formulations, administration and pharmacology.See blog for further informationhttps://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

12 Jan 202218min

Methadone pharmacokinetics and interactions

Methadone pharmacokinetics and interactions

Episode 21 of Cracking Addiction explores methadone pharmacokinetics, breakdown and interactions within the body and interactions with other drugs.Methadone is a drug with a wide variability in its absorption with oral bio-availability ranges from 35% to 100%. This is a significant amount of variability and explains why the same dose of Methadone can impact different patients differently. Methadone is metabolised within the liver by the cytochrome P450 enzymes but mainly 3A4. There is a 17-fold inter-individual variation of methadone blood concentration for a given dosage and variations in metabolism account for a large part of this variation. Kinetic interactions influenced by the CYP 450 enzyme can affect plasma methadone levels.• Inducers of CYP450 can• Accelerate the metabolism of methadone• lower methadone plasma levels• Precipitate opioid withdrawal • Inhibitors of CYP450 can • Slow the metabolism of methadone• Increase plasma levels• Produce opioid toxicity (sedation, overdose)Methadone is excreted renally with approximately 10% of drug renally eliminated unchanged. Renal excretion of methadone urinary pH dependent with increased Methadone excretion noted at pH less than 6 and decreased Methadone excretion at higher pH levels.About Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

22 Dec 202116min

Methadone pharmacology and induction

Methadone pharmacology and induction

Episode 20 of Cracking Addiction explores methadone, its origins, the pharmacology behind methadone and how to commence a patient on Methadone.Methadone is a synthetic long acting mu receptor agonist suitable for the treatment of opioid use disorder. Methadone has a longer plasma half life than morphine (average 22 hours (15-32 hours) vs 2 hours for morphine) which permits once daily supervised dosing.https://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

15 Dec 202122min

Opioid use disorder Post Partum

Opioid use disorder Post Partum

Episode 19 of Cracking Addiction explores the management of opioid use disorder in the post partum period.Post birth the patient's usual oral methadone dose can be continued in the peripartum and post partum period. There is a theoretical concern in the postpartum period of over-sedation as methadone levels may increase as plasma volume and hepatic clearance normalise post the delivery of the child. Latest Blogshttps://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

9 Dec 202111min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
alska-oss
inga-beiga-morsor
johannes-hansen-podcast
angestpodden
rss-viktmedicinpodden
not-fanny-anymore
sexnoveller-deluxe
rss-the-house-podcast-3
sova-med-dan-horning
rss-sjalsligt-avkladd
brottarbroder
handen-pa-hjartat
sa-in-i-sjalen
tyngre-radio
sag-det-bara
rss-the-house-podcast-4
halsoveckan-by-tyngre
rss-angra-inget-3